No Data
No Data
Mesoblast Limited Completes Strategic Share Placement
JPMorgan Chase & Co. Ceases Substantial Holding in Mesoblast Limited
Bell Potter Remains a Buy on Mesoblast Limited (MEOBF)
Mesoblast Price Target Raised to A$3.90/Share From A$1.40 by Bell Potter
First FDA-Approved Mesenchymal Stromal Cell Therapy Ushers in a New Era of Regenerative Medicine
Mesoblast Substantial Holding Changes Signal Institutional Strategy Shift